All In Biotech

Drug Trial Radar · NCT03650114

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,882

Actual

Start

Dec 28, 2018

Primary completion

Sep 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS). COVID-19 sub-study: The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • OfatumumabBiological

    subcutaneous injection of 20 mg ofatumumab every 4 weeks

  • Tetanus toxoid (TT) containing vaccine (Td, Tdap)Biological

    0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid

  • 13-valent pneumococcal conjugate vaccine (13-PCV)Biological

    0.5mL Vial/Syringe

  • 23-valent pneumococcal polysaccharide vaccine (23-PPV)Biological

    0.5mL Vial/Syringe

  • Seasonal Quadrivalent influenza vaccineBiological

    Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)

  • Keyhole limpet hemocyanin (KLH) neo-antigenBiological

    1mg Vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients that experience an adverse event or abnormal laboratory, vital and/or ECG results and positive suicidiality outcomesTime frame: Up to 8 years

Locations

295 sites in 37 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • North Central Neurology Associates PC

    Cullman, Alabama

  • Barrow Neurological Clinics at St Josephs Hospital and MC

    Phoenix, Arizona

  • Fullerton Neuro and Headache Ctr

    Fullerton, California

  • University of California Davis

    Sacramento, California

  • CU Anschutz Med Campus

    Aurora, Colorado

  • Mountain Neuro Research Center PC

    Basalt, Colorado

  • Alpine Clinical Research Center

    Boulder, Colorado

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • Colorado Neurological Research PC

    Denver, Colorado

  • University of Colorado Health Neurology

    Fort Collins, Colorado

  • Christiana Care Health Services

    Newark, Delaware

  • Jem Research Institute

    Atlantis, Florida

  • Neurology Offices of South Florida PLLC

    Delray Beach, Florida

  • Infinity Clinical Research LLC

    Hollywood, Florida

  • Homestead Assoc In Research Inc

    Homestead, Florida

  • Neurology Associates PA

    Maitland, Florida

  • UM Department Of Neurology

    Miami, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • MS and Neuromuscular Center of Excellence

    Oldsmar, Florida

  • Neurology Associates of Ormond Beach

    Ormond Beach, Florida

  • Emerald Coast Neurology

    Pensacola, Florida

  • Neurostudies Inc

    Port Charlotte, Florida

  • Negroski Neurology

    Sarasota, Florida

  • Roskamp Institute Inc

    Sarasota, Florida

  • AMO Corporation

    Tallahassee, Florida

  • Clinical Research of West Florida Inc

    Tampa, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • University Of South Florida

    Tampa, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Velocity Clinical Research

    Savannah, Georgia

  • Georgia Neurology and Sleep Medicine Assoc

    Suwanee, Georgia

  • Hawaii Pacific Neuroscience LLC

    Honolulu, Hawaii

  • Rush University Medical Center

    Chicago, Illinois

  • Consultants in Neurology

    Northbrook, Illinois

  • Josephson Wallack Munshower Neurology PC

    Indianapolis, Indiana

  • University of Kansas Hospital

    Kansas City, Kansas

  • College Park Family Care Center

    Overland Park, Kansas

  • Neuro Medical Clinic of Cenla LLC

    Alexandria, Louisiana

  • The Neuromedical Center

    Baton Rouge, Louisiana

Showing 40 of 295 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.